Clinical trial · Interventional
A Comparison of Morphine and Morphine Plus Dexmedetomidine in Chronic Cancer Pain
NCT02289261CI-TRIAL-00033346completedPhase 4ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine whether dexmedetomidine added to morphine is effective in the treatment of chronic cancer pain.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Chronic Pain | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Morphine | Drug | — | UNRESOLVED |
| Morphine plus dexmedetomidine | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Control
- description
- Morphine, 0.02 mg/kg PCA bolus dose with 10 minutes lock-out interval
- interventionNames
- Drug: Morphine
- type
- ACTIVE_COMPARATOR
- label
- Morphine plus dexmedetomidine
- description
- Morphine 0.02 mg/kg plus dexmedetomidine 0.1 microgram/kg PCA bolus dose with 10 minutes lock-out interval
- interventionNames
- Drug: Morphine plus dexmedetomidine
Primary outcomes (1)
- measure
- Morphine consumption (mg)
- timeFrame
- 24 hours
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * patients with chronic cancer pain * between 20-80 years old age Exclusion Criteria: * the presence of severe systemic disease(cardiac, pulmonary, hepatic or renal) * psychiatric or neurologic disease * unable to communicate verbally * nausea and vomiting * patient's refusal
References
Publications (2)
- BACKGROUNDBlaudszun G, Lysakowski C, Elia N, Tramer MR. Effect of perioperative systemic alpha2 agonists on postoperative morphine consumption and pain intensity: systematic review and meta-analysis of randomized controlled trials. Anesthesiology. 2012 Jun;116(6):1312-22. doi: 10.1097/ALN.0b013e31825681cb. PMID 22546966
- RESULTLin TF, Yeh YC, Lin FS, Wang YP, Lin CJ, Sun WZ, Fan SZ. Effect of combining dexmedetomidine and morphine for intravenous patient-controlled analgesia. Br J Anaesth. 2009 Jan;102(1):117-22. doi: 10.1093/bja/aen320. Epub 2008 Nov 5. PMID 18987053